L3VLUP
ProSign in

PFE · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PFELLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PFE
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterPFELLY
Q3 202027 holders, $24.9bn33 holders, $14.1bn
Q4 202024 holders, $24.4bn29 holders, $17.3bn
Q1 202128 holders, $22.8bn24 holders, $23.0bn
Q2 202125 holders, $25.0bn24 holders, $27.8bn
Q3 202135 holders, $27.3bn31 holders, $29.9bn
Q4 202134 holders, $38.6bn31 holders, $34.7bn
Q1 202234 holders, $33.0bn24 holders, $35.3bn
Q2 202226 holders, $33.9bn33 holders, $42.7bn
Q3 202235 holders, $28.7bn31 holders, $43.4bn
Q4 202232 holders, $32.8bn31 holders, $46.6bn
Q1 202335 holders, $27.0bn33 holders, $44.3bn
Q2 202331 holders, $23.0bn37 holders, $59.6bn
Q3 202337 holders, $22.0bn44 holders, $67.6bn
Q4 202333 holders, $18.8bn45 holders, $73.6bn
Q1 202429 holders, $15.2bn41 holders, $95.3bn
Q2 202432 holders, $14.6bn43 holders, $110bn
Q3 202429 holders, $13.2bn45 holders, $107bn
Q4 202434 holders, $11.4bn46 holders, $93.9bn
Q1 202534 holders, $9.3bn42 holders, $98.4bn
Q2 202528 holders, $7.8bn43 holders, $93.2bn
Q3 202529 holders, $7.4bn39 holders, $86.7bn
Q4 202526 holders, $6.4bn41 holders, $123bn
Q1 202624 holders, $7.9bn39 holders, $106bn
Q2 202622 holders, $5.2bn44 holders, $132bn
PFE

Pfizer Inc

Holders
28
Reported value
$7.8bn
Buyers
16
Sellers
14

Breadth +2 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
43
Reported value
$93.2bn
Buyers
25
Sellers
22

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 50 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PFE (7)

Arrowstreet Capital LP, Bridgewater Associates LP, Caxton Associates LLP, Jane Street Group LLC, Starboard Value LP, Susquehanna International Group LLP, Voloridge Investment Management LLC

Only LLY (22)

Artisan Partners LP, Capital Research Global Investors, Coatue Management LLC, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Freestone Grove Partners LP, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Marshall Wace LLP, Maverick Capital Ltd, Moore Capital Management LP, Point72 Asset Management LP, Polen Capital Management LLC, Quantbot Technologies LP, Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC, Tiger Global Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Viking Global Investors LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →